Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 7/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323108 | 0.84 | XIAP (0.36) | MAP2K1BRD4MAPTBTK | |
| SCHEMBL24374901 | 0.80 | BTK (0.40) | MAP2K1POLBGAATDP1BRD4 | |
| SCHEMBL107748 | 0.79 | MAPK8 (0.45) | MAP2K1GRM5MAPTBTK | |
| SCHEMBL105801 | 0.78 | MEN1 (0.47) | POLBGAABRD4BTK | |
| SCHEMBL29742044 | 0.78 | MEN1 (0.47) | POLBGAABRD4BTK | |
| SCHEMBL14913184 | 0.78 | HTR3A (0.43) | BTK | |
| SCHEMBL31158079 | 0.78 | HTR3A (0.43) | BTK | |
| SCHEMBL16790973 | 0.77 | BRD4 (0.37) | BRD4GRM5BTK | |
| SCHEMBL16766621 | 0.77 | BTK (0.37) | MAP2K1BTK | |
| SCHEMBL16790985 | 0.77 | BTK (0.35) | BRD4GRM5BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077384-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | HOFFMANN LA ROCHE (CH) | 2017-09-06 | — | — | EP | disclosed |
| EP-3077384-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | HOFFMANN LA ROCHE (CH) | 2017-09-06 | — | — | EP | disclosed |
| EP-3077384-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | F. Hoffmann-La Roche AG (CH) | 2016-10-12 | — | — | EP | disclosed |
| US-9260415-B2 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | GENENTECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260415-B2 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | GENENTECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260415-B2 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | GENENTECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2015082583-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015082583-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | BTK, TYK2, LCK | MAP2K1 46/4885POLB 1457/4885GAA 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.